论文部分内容阅读
不同急性淋巴细胞白血病患者的预后存在差异,部分患者会由于复发难治而失去生命,其难以根治的原因之一是体内存在白血病干细胞,而目前由于白血病细胞对对化疗药物产生耐药,严重阻碍了急性淋巴细胞白血病的治疗。伴随着人们对急性淋巴细胞白血病的分子生物学机制不断深入了解,全基因组学研究进一步拓展了对其发病机制及预后的认识,发现了众多肿瘤细胞的耙点,而基于靶点的生物技术在临床不断被应用并取得了显著的疗效。随着医学技术的快速发展,把向治疗的地位越来越重要。本文主要对该病草巴向治疗的方法、机制及现状进行了综述。
The prognosis of patients with different acute lymphoblastic leukemia is different, some patients will be refractory to relapse due to the loss of life, one of the reasons it is difficult to cure the body of leukemia stem cells exist, and now due to leukemia cells on the chemotherapeutic drug resistance, a serious obstacle Acute lymphoblastic leukemia treatment. With the continuous understanding of the molecular biological mechanism of acute lymphoblastic leukemia, genome-wide study has further expanded the understanding of its pathogenesis and prognosis, found many rake points of tumor cells, and target-based biotechnology Clinical application has been made and achieved remarkable results. With the rapid development of medical technology, the status of treatment has become more and more important. This article mainly summarizes the methods, mechanism and current situation of this disease-free treatment.